262 related articles for article (PubMed ID: 32464226)
1. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent.
Jensen ME; Galli A; Thomsen M; Jensen KL; Thomsen GK; Klausen MK; Vilsbøll T; Christensen MB; Holst JJ; Owens A; Robertson S; Daws L; Zanella D; Gether U; Knudsen GM; Fink-Jensen A
Neurochem Int; 2020 Sep; 138():104772. PubMed ID: 32464226
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels.
Reddy IA; Pino JA; Weikop P; Osses N; Sørensen G; Bering T; Valle C; Bluett RJ; Erreger K; Wortwein G; Reyes JG; Graham D; Stanwood GD; Hackett TA; Patel S; Fink-Jensen A; Torres GE; Galli A
Transl Psychiatry; 2016 May; 6(5):e809. PubMed ID: 27187231
[TBL] [Abstract][Full Text] [Related]
3. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum.
Dickinson SD; Sabeti J; Larson GA; Giardina K; Rubinstein M; Kelly MA; Grandy DK; Low MJ; Gerhardt GA; Zahniser NR
J Neurochem; 1999 Jan; 72(1):148-56. PubMed ID: 9886065
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes.
Midde NM; Gomez AM; Zhu J
J Neuroimmune Pharmacol; 2012 Sep; 7(3):629-39. PubMed ID: 22570010
[TBL] [Abstract][Full Text] [Related]
6. 3,4-Methylenedioxymethamphetamine (MDMA) Alters Synaptic Dopamine Release in the Dorsal Striatum Through Nicotinic Receptors and DAT Inhibition.
Rizzo FR; Federici M; Mercuri NB
Neuroscience; 2018 May; 377():69-76. PubMed ID: 29510210
[TBL] [Abstract][Full Text] [Related]
7. Mice expressing markedly reduced striatal dopamine transporters exhibit increased locomotor activity, dopamine uptake turnover rate, and cocaine responsiveness.
Rao A; Sorkin A; Zahniser NR
Synapse; 2013 Oct; 67(10):668-77. PubMed ID: 23564231
[TBL] [Abstract][Full Text] [Related]
8. SKF-83566, a D1-dopamine receptor antagonist, inhibits the dopamine transporter.
Stouffer MA; Ali S; Reith ME; Patel JC; Sarti F; Carr KD; Rice ME
J Neurochem; 2011 Sep; 118(5):714-20. PubMed ID: 21689106
[TBL] [Abstract][Full Text] [Related]
9. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA
J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
[TBL] [Abstract][Full Text] [Related]
10. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T
Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804
[TBL] [Abstract][Full Text] [Related]
11. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
[TBL] [Abstract][Full Text] [Related]
12. Melatonin receptors limit dopamine reuptake by regulating dopamine transporter cell-surface exposure.
Benleulmi-Chaachoua A; Hegron A; Le Boulch M; Karamitri A; Wierzbicka M; Wong V; Stagljar I; Delagrange P; Ahmad R; Jockers R
Cell Mol Life Sci; 2018 Dec; 75(23):4357-4370. PubMed ID: 30043140
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in striatal dopaminergic function within heterozygous mutant dopamine transporter knock-out mice.
Ji J; Dluzen DE
J Neural Transm (Vienna); 2008 Jun; 115(6):809-17. PubMed ID: 18197357
[TBL] [Abstract][Full Text] [Related]
14. Neuronal dopamine transporter activity, density and methamphetamine inhibition are differentially altered in the nucleus accumbens and striatum with no changes in glycosylation in rats behaviorally sensitized to methamphetamine.
Bjorklund NL; Sorg BA; Schenk JO
Synapse; 2008 Oct; 62(10):736-45. PubMed ID: 18651643
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 transgenic rats display an increase in [(3)H]dopamine uptake in the prefrontal cortex and striatum.
Zhu J; Yuan Y; Midde NM; Gomez AM; Sun WL; Quizon PM; Zhan CG
J Neurovirol; 2016 Jun; 22(3):282-92. PubMed ID: 26501780
[TBL] [Abstract][Full Text] [Related]
16. PICK1-Deficient Mice Exhibit Impaired Response to Cocaine and Dysregulated Dopamine Homeostasis.
Jensen KL; Sørensen G; Dencker D; Owens WA; Rahbek-Clemmensen T; Brett Lever M; Runegaard AH; Riis Christensen N; Weikop P; Wörtwein G; Fink-Jensen A; Madsen KL; Daws L; Gether U; Rickhag M
eNeuro; 2018; 5(3):. PubMed ID: 29911172
[TBL] [Abstract][Full Text] [Related]
17. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
[TBL] [Abstract][Full Text] [Related]
18. Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism.
Kivell B; Uzelac Z; Sundaramurthy S; Rajamanickam J; Ewald A; Chefer V; Jaligam V; Bolan E; Simonson B; Annamalai B; Mannangatti P; Prisinzano TE; Gomes I; Devi LA; Jayanthi LD; Sitte HH; Ramamoorthy S; Shippenberg TS
Neuropharmacology; 2014 Nov; 86():228-40. PubMed ID: 25107591
[TBL] [Abstract][Full Text] [Related]
19. Enhanced dopamine transporter function in striatum during nicotine withdrawal.
Hadjiconstantinou M; Duchemin AM; Zhang H; Neff NH
Synapse; 2011 Feb; 65(2):91-8. PubMed ID: 20506223
[TBL] [Abstract][Full Text] [Related]
20. Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease.
Afonso-Oramas D; Cruz-Muros I; Alvarez de la Rosa D; Abreu P; Giráldez T; Castro-Hernández J; Salas-Hernández J; Lanciego JL; Rodríguez M; González-Hernández T
Neurobiol Dis; 2009 Dec; 36(3):494-508. PubMed ID: 19766189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
